SiSaf is an RNA delivery and therapeutics company. Its proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon.The company’s Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improvethe stability, safety, and transfection efficiency of RNA. SiSaf uses sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and is maximizing the potential of its technology through research partnerships.Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, it has fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.

Biotechnology

Health Care

Pharmaceutical

SiSaf Ltd

Dr Suzanne Saffie-Siebert

Tim Brundle

Richard Scarrott

Nissim Torabi-Pour

John Stanton

Joanne Manson

Flavia M. Sutera

Charles Weatherstone

Andy Gibson

Leadership Team

Operations Team

Research and Development

Teams at SiSaf Ltd

Leadership Team

Operations Team

Research and Development